Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Author: sugaradmin

1252-OR: Diabetes, Dietary, and Behavioral Findings in a Food Is Medicine Intervention in Youth with Prediabetes and Type 2 Diabetes

June 8, 2026 by sugaradmin

Introduction and Objective: Lifestyle interventions are the foundation of prediabetes (pre-DM) and type 2 diabetes (T2D) management. High levels of food insecurity hinder the ability to create healthy eating habits. Prospective food is medicine intervention studies have not been conducted in pediatric T2D populations to date. This ongoing prospective study evaluates the efficacy of a […]

Read More
DiabetesLeave a Comment on 1252-OR: Diabetes, Dietary, and Behavioral Findings in a Food Is Medicine Intervention in Youth with Prediabetes and Type 2 Diabetes

1257-OR: Glucose Control during Three-Month Treatment with a Bihormonal Artificial Pancreas vs. Current Diabetes Care in Patients following Total Pancreatectomy (PANORAMA): A Randomised Crossover Trial

June 8, 2026 by sugaradmin

Introduction and Objective: In patients undergoing total pancreatectomy (TP), adequate glycemic control is a major concern. Previously, a 7-day treatment with a bihormonal artificial pancreas (BIHAP), delivering both insulin and glucagon for fully closed-loop regulation, improved glycemic control. However, evidence on its long-term efficacy is lacking.Methods: This randomised open-label crossover trial compared BIHAP treatment with […]

Read More
DiabetesLeave a Comment on 1257-OR: Glucose Control during Three-Month Treatment with a Bihormonal Artificial Pancreas vs. Current Diabetes Care in Patients following Total Pancreatectomy (PANORAMA): A Randomised Crossover Trial

1233-OR: Postmeal Glucose Patterns as Early Predictors of Gestational Diabetes

June 8, 2026 by sugaradmin

Introduction and Objective: Gestational Diabetes Mellitus (GDM) screening at 24-28 weeks limits early intervention. Emerging studies, such as GLAM, have evaluated early screening using Continuous Glucose Monitoring (CGM) and standard metrics (e.g., TA140) as biomarkers, showing promising results. We hypothesize that novel features derived from post-prandial (PP) glucose profiles can outperform standard CGM metrics and […]

Read More
DiabetesLeave a Comment on 1233-OR: Postmeal Glucose Patterns as Early Predictors of Gestational Diabetes

1259-OR: Precise Carbohydrate Counting vs. Estimated Counting in Adults with Type 1 Diabetes Using mylife YpsoPump Advanced Hybrid Closed-Loop System: A Pilot Project Comparing Glycaemic Outcomes

June 8, 2026 by sugaradmin

Introduction and Objective: Carbohydrate counting is perceived as one of the most burdensome tasks in Type 1 Diabetes (T1D) but meta-analyses have shown it is an effective method in reducing HbA1c. We compared glycemic control in adults with T1D using mylife YpsoPump with advanced hybrid closed loop (HCL) system (mylife CamAPS FX app) among those […]

Read More
DiabetesLeave a Comment on 1259-OR: Precise Carbohydrate Counting vs. Estimated Counting in Adults with Type 1 Diabetes Using mylife YpsoPump Advanced Hybrid Closed-Loop System: A Pilot Project Comparing Glycaemic Outcomes

1246-OR: Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials

June 8, 2026 by sugaradmin

Introduction and Objective: Enlicitide is an oral PCSK9 inhibitor that, in two Phase 3 randomized, placebo-controlled trials, demonstrated LDL-C reduction of approximately 60% and was well tolerated. Here we report the efficacy of enlicitide in participants with and without diabetes mellitus (DM) at baseline, and the incidence of new onset or worsening diabetes.Methods: CORALreef Lipids […]

Read More
DiabetesLeave a Comment on 1246-OR: Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Participants with and without Diabetes Mellitus in a Pooled Analysis of Two Phase 3 Trials

1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

June 8, 2026 by sugaradmin

Introduction and Objective: To evaluate the efficacy and safety of mazdutide 6 mg vs semaglutide 1 mg in Chinese T2D patients (pts) with obesity who had inadequately glycaemic control and suboptimal weight loss (WL) following lifestyle interventions with or without metformin (NCT06184568).Methods: A total of 349 pts aged ≥18 years with T2D duration ≤10 years […]

Read More
DiabetesLeave a Comment on 1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial

1273-OR: Revolutionizing Cardiac Health: Unlocking the Power of Oral Ketones to Boost Cardiac Efficiency, Changes in Insulin Secretion, and Cardiometabolic Outcomes

June 8, 2026 by sugaradmin

Introduction and Objective: Heart Failure (HF) in T2D is common and increases mortality. IV Ketone infusion improves EF% ~6% at 3hrs in patients with T2D and HFrEF. Oral ketones (OKE) have shown similar results. Here, we evaluate the effect of chronic OKE administration (7 days) on cardiac efficiency.Methods: 12 subjects with T2D and HFrEF underwent […]

Read More
DiabetesLeave a Comment on 1273-OR: Revolutionizing Cardiac Health: Unlocking the Power of Oral Ketones to Boost Cardiac Efficiency, Changes in Insulin Secretion, and Cardiometabolic Outcomes

1172-OR: Age-Specific Remote Education Facilitates Successful CGM Use in Older Adults with Diabetes Using Insulin

June 8, 2026 by sugaradmin

Introduction and Objective: CGM uptake remains limited in insulin-using older population in spite of data showing its effectiveness in improving glycemic control and lowering hypoglycemia risk. Whether remote education with strategies to overcome age-related barriers can improve adoption of CGM in older population is not known.Methods: In this prospective 6-month intervention study, we enrolled older […]

Read More
DiabetesLeave a Comment on 1172-OR: Age-Specific Remote Education Facilitates Successful CGM Use in Older Adults with Diabetes Using Insulin

1165-OR: Predictors of Diabetes Remission and Relapse after Metabolic Bariatric Surgery vs. Medical Lifestyle Intervention: The ARMMS-T2D Study

June 8, 2026 by sugaradmin

Introduction and Objective: Metabolic-bariatric surgery (MBS) is highly effective vs. medical-lifestyle intervention (MLI) for ameliorating T2D and promoting remission. Previous models of patient characteristics to predict T2D remission and relapse have used retrospective observational data, often without directly comparing different MBS procedures. The current study identifies clinical characteristics that predict T2D remission and relapse over […]

Read More
DiabetesLeave a Comment on 1165-OR: Predictors of Diabetes Remission and Relapse after Metabolic Bariatric Surgery vs. Medical Lifestyle Intervention: The ARMMS-T2D Study

1197-OR: Visceral Adipose Tissue ICOS hi Treg Cells Mitigates Systemic Metabolic Dysregulation in Diet-Induced Obese Mice

June 7, 2026 by sugaradmin

Introduction and Objective: Regulatory T (Treg) cells serve essential roles in immune tolerance and systemic tissue homeostasis remodeling under distinct physiological and pathological conditions. Visceral adipose tissue (VAT) Treg cells constitute a heterogeneous population capable of responding to diverse microenvironmental signals, however, the precise mechanisms by which VAT Treg cells regulate adipose tissue metabolic homeostasis […]

Read More
DiabetesLeave a Comment on 1197-OR: Visceral Adipose Tissue ICOS hi Treg Cells Mitigates Systemic Metabolic Dysregulation in Diet-Induced Obese Mice

Posts navigation

Older posts
Newer posts

Recent Posts

  • ‘Ozempic Feet:’ What Causes This Unusual GLP-1 Side Effect?
  • Depo-Provera, IUDs Tied to Higher Brain Tumor Risk
  • Trends in self-reported current diabetes care use, socioeconomic inequalities, and associated factors in Japan: evidence from the Comprehensive Survey of Living Conditions (1986-2022)
  • Bryan Johnson Diagnosed with Autoimmune Gastritis
  • Sam Neill, ‘Jurassic Park’ Star, Dies at 78

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness